Showing 1 - 20 results of 34 for search 'Claudio Jommi', query time: 0.06s Refine Results
  1. 1

    Title not available by Claudio Jommi

    Published 2015-09-01
    Get full text
    Article
  2. 2
    The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)

    The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA) by Claudio Jommi, Roberto Ravasio

    Published 2019-11-01
    Get full text
    Article
  3. 3

    Title not available by Carlo Lucioni, Claudio Jommi

    Published 2019-11-01
    Get full text
    Article
  4. 4
    Value of health technologies, HTA and decisions

    Value of health technologies, HTA and decisions by Carlo Lucioni, Claudio Jommi

    Published 2016-12-01
    Get full text
    Article
  5. 5
    Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals

    Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals by Claudio Jommi, Marianna Cavazza

    Published 2019-07-01
    Get full text
    Article
  6. 6
    The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy

    The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy by Monica Hildegard Otto, Monica Hildegard Otto, Carla Pillarella, Claudio Jommi, Claudio Jommi

    Published 2018-10-01
    Get full text
    Article
  7. 7
    Corrigendum: The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy

    Corrigendum: The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy by Monica Hildegard Otto, Monica Hildegard Otto, Carla Pillarella, Claudio Jommi, Claudio Jommi

    Published 2019-03-01
    Get full text
    Article
  8. 8
    Price and reimbursement of medicines when new indications are approved: the results of a survey on ISPOR Italy Rome Chapter members

    Price and reimbursement of medicines when new indications are approved: the results of a survey on ISPOR Italy Rome Chapter members by Claudio Jommi, Eugenio Di Brino

    Published 2023-05-01
    Get full text
    Article
  9. 9
    Current pipelines for neglected diseases.

    Current pipelines for neglected diseases. by Paolo di Procolo, Claudio Jommi

    Published 2014-09-01
    Get full text
    Article
  10. 10

    Title not available by Carla Rognoni, Arianna Bertolani, Claudio Jommi

    Published 2018-06-01
    Get full text
    Article
  11. 11
    Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives

    Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives by Carla Rognoni, Arianna Bertolani, Claudio Jommi

    Published 2018-06-01
    Get full text
    Article
  12. 12

    Title not available by Claudio Jommi, MSc, Arianna Bertolani, Phd

    Published 2018-04-01
    Get full text
    Article
  13. 13
    Patients’ Associations and HTA for medicines: actual and future role in Italy

    Patients’ Associations and HTA for medicines: actual and future role in Italy by Claudio Jommi MSc, Arianna Bertolani Phd

    Published 2018-04-01
    Get full text
    Article
  14. 14
    Unmet need: definitions, literature evidence and implications for HTA

    Unmet need: definitions, literature evidence and implications for HTA by Claudio Jommi, Michela Meregaglia, Carmine Pinto

    Published 2023-10-01
    Get full text
    Article
  15. 15
    The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study

    The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study by Arianna Bertolani, Roberto Ravasio, Paola Raimondo, Claudio Jommi

    Published 2022-07-01
    Get full text
    Article
  16. 16

    Title not available by Claudio Jommi, Francesco S. Mennini, Pier L. Canonico, Paolo Bruzzi

    Published 2016-11-01
    Get full text
    Article
  17. 17
    The future of Funds for Innovative Medicines: results from a Delphi Study

    The future of Funds for Innovative Medicines: results from a Delphi Study by Claudio Jommi, Patrizio Armeni, Arianna Bertolani, Francesco Costa, Monica Otto

    Published 2021-03-01
    Get full text
    Article
  18. 18
    Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?

    Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? by Virginia Ronco, Myriam Dilecce, Elena Lanati, Pier Luigi Canonico, Claudio Jommi

    Published 2021-12-01
    Get full text
    Article
  19. 19

    Title not available by Federico Villa, Claudio Jommi, Armando Genazzani, Sara Antignani, Simona Montilla, Mario Melazzini

    Published 2018-08-01
    Get full text
    Article
  20. 20
    Accesso precoce al mercato: dalle approvazioni condizionate di EMA agli accordi negoziali particolari di AIFA

    Accesso precoce al mercato: dalle approvazioni condizionate di EMA agli accordi negoziali particolari di AIFA by Federico Villa, Claudio Jommi, Armando Genazzani, Sara Antignani, Simona Montilla, Mario Melazzini

    Published 2018-08-01
    Get full text
    Article

Search Tools: